Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery
Rajaganapathy Kaliyaperumal,Srinivasan Ranganathan,Masilamani Krishnamoorthy,Vasanth Kumar Mohan,Senthilnathan Balaraman,Gowri Rajapandian,Ramalingam Sathiyasundar,Saravanan Ravindran
DOI: https://doi.org/10.2174/0126673878260516231017165459
Abstract:The development of Monoclonal antibodies (mAbs) has also allowed researchers to understand the complexity of diseases better and find new treatments for difficult-to-treat conditions. Using mAbs, researchers can identify and target specific molecules in the body involved in the disease process. This has allowed for a more targeted treatment approach, which has resulted in improved outcomes for many patients. This hypothesis has been the basis for the development of mAbs that can target an array of illnesses. In the past two decades, therapeutic mAbs have been developed to treat cancer, autoimmune diseases, cardiovascular diseases, and metabolic diseases. For instance, using mAbs has improved outcomes in treating rheumatoid arthritis, multiple sclerosis, and Crohn's disease. However, delivering mAbs in biological systems remains a significant challenge in drug delivery. This is due to their large size, low stability in circulation, and difficulties in achieving their desired action in the target cells. Monoclonal antibodies (mAbs) are an essential tool in biological systems, as they can be used to deliver drugs to specific cell types or tissues. Cloning methods of monoclonal antibody production have been developed to produce mAbs with therapeutic potential. Hence, the present review focused on the development and drug delivery of Monoclonal antibodies (mAbs) in biological systems, which includes cloning methods, various drug delivery technologies, formulation production technology, and its applications in multiple diseases were focused for this review.